| NCT01896479 |
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT01896479 |
Active, not recruiting |
Exelixis |
2020-09-30 |
| NCT04211337 |
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT04211337 |
Recruiting |
Eli Lilly and Company |
2023-02-17 |
| NCT03736720 |
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin |
https://ClinicalTrials.gov/show/NCT03736720 |
Recruiting |
Roswell Park Cancer Institute |
2021-09-05 |
| NCT03333616 |
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
https://ClinicalTrials.gov/show/NCT03333616 |
Recruiting |
Dana-Farber Cancer Institute |
2021-05-31 |
| NCT03279614 |
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT03279614 |
Recruiting |
Peking University |
2019-09-01 |
| NCT03278405 |
Avelumab in G3 NEC |
https://ClinicalTrials.gov/show/NCT03278405 |
Completed |
Sunnybrook Health Sciences Centre |
2019-08-09 |
| NCT03246659 |
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC |
https://ClinicalTrials.gov/show/NCT03246659 |
Completed |
Azienda Ospedaliero, Universitaria Pisana |
2018-11-30 |
| NCT03147404 |
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes |
https://ClinicalTrials.gov/show/NCT03147404 |
Completed |
Samsung Medical Center |
2019-07-22 |
| NCT03110978 |
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT03110978 |
Recruiting |
M.D. Anderson Cancer Center |
2022-06-30 |
| NCT03079440 |
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03079440 |
Recruiting |
Asan Medical Center |
2020-12-31 |
| NCT03074513 |
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors |
https://ClinicalTrials.gov/show/NCT03074513 |
Recruiting |
M.D. Anderson Cancer Center |
2021-03-31 |
| NCT03072160 |
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT03072160 |
Completed |
National Institutes of Health Clinical Center (CC) |
2019-11-22 |
| NCT03037385 |
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03037385 |
Recruiting |
Blueprint Medicines Corporation |
2021-12-31 |
| NCT03012620 |
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types |
https://ClinicalTrials.gov/show/NCT03012620 |
Recruiting |
UNICANCER |
2023-01-31 |
| NCT02955069 |
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) |
https://ClinicalTrials.gov/show/NCT02955069 |
Completed |
Novartis |
2018-08-10 |
| NCT02936323 |
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers |
https://ClinicalTrials.gov/show/NCT02936323 |
Active, not recruiting |
Tarveda Therapeutics |
2020-07-31 |
| NCT02856347 |
Prospective Study Evaluating the Medullary Thyroid Cancer Management’s Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin |
https://ClinicalTrials.gov/show/NCT02856347 |
Recruiting |
Institut Claudius Regaud |
2021-04-30 |
| NCT02820857 |
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer |
https://ClinicalTrials.gov/show/NCT02820857 |
Recruiting |
Hospices Civils de Lyon |
2023-03-04 |
| NCT02806648 |
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) |
https://ClinicalTrials.gov/show/NCT02806648 |
Completed |
Grupo Espanol de Tumores Neuroendocrinos |
2017-07-31 |
| NCT02755675 |
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung |
https://ClinicalTrials.gov/show/NCT02755675 |
Recruiting |
Rigshospitalet, Denmark |
2023-04-30 |
| NCT02754297 |
Personalized PRRT of Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02754297 |
Recruiting |
CHU de Quebec-Universite Laval |
2021-04-30 |
| NCT02695459 |
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin |
https://ClinicalTrials.gov/show/NCT02695459 |
Recruiting |
The Netherlands Cancer Institute |
2020-06-30 |
| NCT02687958 |
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin |
https://ClinicalTrials.gov/show/NCT02687958 |
Recruiting |
Gruppo Oncologico Italiano di Ricerca Clinica |
2021-12-31 |
| NCT02595424 |
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02595424 |
Recruiting |
Eastern Cooperative Oncology Group |
2024-01-01 |
| NCT02586350 |
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) |
https://ClinicalTrials.gov/show/NCT02586350 |
Completed |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2018-09-30 |
| NCT02834013 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
https://ClinicalTrials.gov/show/NCT02834013 |
Recruiting |
National Cancer Institute (NCI) |
2021-08-31 |
| NCT01229943 |
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT01229943 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-09-01 |
| NCT02893930 |
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02893930 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-07-31 |
| NCT03387592 |
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas |
https://ClinicalTrials.gov/show/NCT03387592 |
Recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2022-01-31 |
| NCT02457273 |
Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients |
https://ClinicalTrials.gov/show/NCT02457273 |
Completed |
National Health Research Institutes, Taiwan |
2018-04-18 |
| NCT02318784 |
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers |
https://ClinicalTrials.gov/show/NCT02318784 |
Active, not recruiting |
SCRI Development Innovations, LLC |
2020-02-01 |
| NCT02315625 |
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery |
https://ClinicalTrials.gov/show/NCT02315625 |
Completed |
National Institutes of Health Clinical Center (CC) |
2019-05-22 |
| NCT02250885 |
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors |
https://ClinicalTrials.gov/show/NCT02250885 |
Completed |
Gabrail Cancer Center Research |
2016-08-31 |
| NCT02248012 |
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) |
https://ClinicalTrials.gov/show/NCT02248012 |
Completed |
Haukeland University Hospital |
2018-01-31 |
| NCT02236910 |
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours |
https://ClinicalTrials.gov/show/NCT02236910 |
Recruiting |
Lawson Health Research Institute |
2021-09-30 |
| NCT02230176 |
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
https://ClinicalTrials.gov/show/NCT02230176 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2023-10-31 |
| NCT02215447 |
A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas |
https://ClinicalTrials.gov/show/NCT02215447 |
Active, not recruiting |
Barwon Health |
2018-11-30 |
| NCT02113800 |
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study |
https://ClinicalTrials.gov/show/NCT02113800 |
Recruiting |
AIO-Studien-gGmbH |
2019-09-30 |
| NCT02101918 |
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02101918 |
Completed |
National Cancer Institute (NCI) |
2018-01-31 |
| NCT01298323 |
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment |
https://ClinicalTrials.gov/show/NCT01298323 |
Active, not recruiting |
Sanofi |
2013-04-30 |
| NCT03136055 |
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas |
https://ClinicalTrials.gov/show/NCT03136055 |
Recruiting |
University of California, San Francisco |
2022-02-28 |
| NCT03352934 |
Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy |
https://ClinicalTrials.gov/show/NCT03352934 |
Recruiting |
Johannes Gutenberg University Mainz |
2023-01-31 |
| NCT01876771 |
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours |
https://ClinicalTrials.gov/show/NCT01876771 |
Recruiting |
AHS Cancer Control Alberta |
2033-12-31 |
| NCT01873248 |
Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients |
https://ClinicalTrials.gov/show/NCT01873248 |
Completed |
Jonsson Comprehensive Cancer Center |
2017-06-16 |
| NCT01866228 |
Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes |
https://ClinicalTrials.gov/show/NCT01866228 |
Completed |
University of Manitoba |
2017-02-28 |
| NCT01856920 |
QUILT-3.006 for Recurrent Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT01856920 |
Active, not recruiting |
NantCell, Inc. |
2019-12-31 |
| NCT01730638 |
ImmunoTEP for Patients With Medullary Thyroid Carcinoma. |
https://ClinicalTrials.gov/show/NCT01730638 |
Completed |
Nantes University Hospital |
2016-12-31 |
| NCT01661179 |
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma |
https://ClinicalTrials.gov/show/NCT01661179 |
Completed |
Sanofi |
2013-12-31 |
| NCT01642251 |
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT01642251 |
Completed |
National Cancer Institute (NCI) |
2016-12-08 |
| NCT01625520 |
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT01625520 |
Completed |
Federico II University |
2016-03-31 |
| NCT01563354 |
3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial |
https://ClinicalTrials.gov/show/NCT01563354 |
Completed |
Novartis |
2020-02-10 |
| NCT01396382 |
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer |
https://ClinicalTrials.gov/show/NCT01396382 |
Completed |
Vanderbilt-Ingram Cancer Center |
2014-05-31 |
| NCT01365169 |
Post-op Wellness Program for Pancreatic Cancer Patients That Uses Patient Feedback and Real-time Provider Monitoring |
https://ClinicalTrials.gov/show/NCT01365169 |
Recruiting |
M.D. Anderson Cancer Center |
2025-02-25 |
| NCT04280081 |
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation |
https://ClinicalTrials.gov/show/NCT04280081 |
Recruiting |
Eli Lilly and Company |
2021-05-31 |
| NCT04122911 |
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas |
https://ClinicalTrials.gov/show/NCT04122911 |
Completed |
National Cancer Institute, Naples |
2017-12-30 |
| NCT03992911 |
Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT03992911 |
Recruiting |
Peking University |
2022-06-20 |
| NCT03901378 |
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT03901378 |
Recruiting |
Ochsner Health System |
2021-04-30 |
| NCT03858855 |
Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment |
https://ClinicalTrials.gov/show/NCT03858855 |
Completed |
Ohio State University Comprehensive Cancer Center |
2020-04-13 |
| NCT03837977 |
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT03837977 |
Recruiting |
The Christie NHS Foundation Trust |
2021-11-01 |
| NCT03834701 |
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms |
https://ClinicalTrials.gov/show/NCT03834701 |
Recruiting |
Catholic University of the Sacred Heart |
2021-06-01 |
| NCT03728361 |
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer |
https://ClinicalTrials.gov/show/NCT03728361 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-12-31 |
| NCT03623984 |
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers |
https://ClinicalTrials.gov/show/NCT03623984 |
Recruiting |
University of Alabama at Birmingham |
2020-06-07 |
| NCT03600233 |
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03600233 |
Recruiting |
TaiRx, Inc. |
2021-11-30 |
| NCT03591731 |
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) |
https://ClinicalTrials.gov/show/NCT03591731 |
Recruiting |
Intergroupe Francophone de Cancerologie Thoracique |
2021-10-31 |
| NCT03582475 |
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate |
https://ClinicalTrials.gov/show/NCT03582475 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2020-09-01 |
| NCT03517488 |
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03517488 |
Recruiting |
Xencor, Inc. |
2020-12-31 |
| NCT01216267 |
Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples |
https://ClinicalTrials.gov/show/NCT01216267 |
Completed |
University of Western Ontario, Canada |
2012-01-31 |
| NCT01204476 |
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT01204476 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01155258 |
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT01155258 |
Completed |
University of Southern California |
2013-01-31 |
| NCT01121939 |
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers |
https://ClinicalTrials.gov/show/NCT01121939 |
Completed |
SCRI Development Innovations, LLC |
2015-02-28 |
| NCT01010126 |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
https://ClinicalTrials.gov/show/NCT01010126 |
Completed |
National Cancer Institute (NCI) |
2017-03-13 |
| NCT00926640 |
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers |
https://ClinicalTrials.gov/show/NCT00926640 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-06-16 |
| NCT00869050 |
Capecitabine and Temozolomide for Neuroendocrine Cancers |
https://ClinicalTrials.gov/show/NCT00869050 |
Completed |
Columbia University |
2013-12-31 |
| NCT01788982 |
Nintedanib(BIBF1120) in Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT01788982 |
Active, not recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2019-10-31 |
| NCT02867592 |
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors |
https://ClinicalTrials.gov/show/NCT02867592 |
Recruiting |
National Cancer Institute (NCI) |
2020-09-30 |
| NCT04042714 |
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT04042714 |
Recruiting |
Baylor Research Institute |
2023-08-15 |
| NCT03274258 |
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma |
https://ClinicalTrials.gov/show/NCT03274258 |
Recruiting |
M.D. Anderson Cancer Center |
2020-07-01 |
| NCT04079712 |
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04079712 |
Recruiting |
National Cancer Institute (NCI) |
2021-10-01 |
| NCT03866382 |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
https://ClinicalTrials.gov/show/NCT03866382 |
Recruiting |
National Cancer Institute (NCI) |
2023-02-28 |
| NCT03157128 |
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT03157128 |
Recruiting |
Loxo Oncology, Inc. |
2022-03-31 |
| NCT02487095 |
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
https://ClinicalTrials.gov/show/NCT02487095 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2024-05-31 |
| NCT00780663 |
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00780663 |
Completed |
Cylene Pharmaceuticals |
2010-03-31 |
| NCT00663429 |
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00663429 |
Completed |
Callisto Pharmaceuticals |
2010-03-31 |
| NCT00655655 |
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT00655655 |
Completed |
Mayo Clinic |
2009-09-15 |
| NCT00625846 |
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT00625846 |
Completed |
National Cancer Institute (NCI) |
2018-12-21 |
| NCT00607113 |
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00607113 |
Completed |
M.D. Anderson Cancer Center |
2011-10-31 |
| NCT00514046 |
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT00514046 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2019-12-10 |
| NCT00511862 |
TheraSphere for the Treatment of Liver Metastases |
https://ClinicalTrials.gov/show/NCT00511862 |
Completed |
BTG International Inc. |
2011-03-31 |
| NCT00454363 |
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer |
https://ClinicalTrials.gov/show/NCT00454363 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT00423254 |
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. |
https://ClinicalTrials.gov/show/NCT00423254 |
Completed |
Mannkind Corporation |
2009-09-30 |
| NCT00410761 |
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT00410761 |
Active, not recruiting |
Sanofi |
2009-07-31 |
| NCT00390325 |
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT00390325 |
Active, not recruiting |
National Cancer Institute (NCI) |
2017-01-30 |
| NCT00388063 |
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00388063 |
Completed |
Callisto Pharmaceuticals |
NA |
| NCT00381641 |
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00381641 |
Active, not recruiting |
National Cancer Institute (NCI) |
2016-12-31 |
| NCT00363051 |
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy |
https://ClinicalTrials.gov/show/NCT00363051 |
Completed |
Novartis |
2008-01-31 |
| NCT00358956 |
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer |
https://ClinicalTrials.gov/show/NCT00358956 |
Completed |
Sanofi |
2008-01-31 |
| NCT00353015 |
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract |
https://ClinicalTrials.gov/show/NCT00353015 |
Completed |
M.D. Anderson Cancer Center |
2007-12-31 |
| NCT00193531 |
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00193531 |
Completed |
SCRI Development Innovations, LLC |
2007-01-31 |
| NCT00113360 |
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00113360 |
Completed |
M.D. Anderson Cancer Center |
2009-07-31 |
| NCT00093782 |
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00093782 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00003549 |
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer |
https://ClinicalTrials.gov/show/NCT00003549 |
Completed |
Southwest Oncology Group |
2001-09-30 |
| NCT00079131 |
Oblimersen in Treating Patients With Merkel Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00079131 |
Completed |
National Cancer Institute (NCI) |
2007-01-31 |
| NCT00004922 |
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00004922 |
Completed |
Memorial Sloan Kettering Cancer Center |
2002-06-30 |
| NCT00068783 |
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer |
https://ClinicalTrials.gov/show/NCT00068783 |
Completed |
National Cancer Institute (NCI) |
2007-06-30 |
| NCT00019786 |
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases |
https://ClinicalTrials.gov/show/NCT00019786 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |